Overview: Nasal ipratropium is used to help reduce symptoms of a runny nose. It works by reducing the amount of liquid and mucus made in your nose. Common side effects can include dryness of the nose, ...
Additionally, the FDA has confirmed that this product is eligible for 180-days of generic drug exclusivity for Ipratropium Bromide HFA Inhalation Aerosol as we were the first ANDA applicant with ...
Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...
Learn everything you need to know about Ipratropium Bromide-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...
Objectives: To compare the efficacy and tolerability of formoterol (12 or 24µg twice daily) alone with combined ipratropium bromide and fenoterol in the treatment of chronic obstructive pulmonary ...
Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
We conducted a cohort study to examine the association between anticholinergic use and CVEs in a cohort with newly diagnosed COPD. In our study, we found an increased risk of CVE associated with the ...
Patients taking ipratropium bromide, an anticholinergic used in the treatment of COPD, may be at an increased risk for cardiovascular events (CVE), including heart failure. Patients taking ipratropium ...
Details concerning the Ipratropium combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and ...
Ipratropium bromide 0.5 mg/3 mL (0.017%), albuterol (as sulfate) 2.5 mg/3 mL (0.083%); soln for inh. Not for primary treatment of acute attack. Avoid excessive use. Discontinue if paradoxical ...
RANCHO CUCAMONGA, CA / / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results